600
Participants
Start Date
June 4, 2024
Primary Completion Date
December 31, 2028
Study Completion Date
May 31, 2029
Methadone
"Drug: Methadone~Possible formulations:~10 and 50 mg tablets"
Buprenorphine (BUP)
"Drug: Buprenorphine (BUP)~Possible formulations:~A. Buprenorphine 225 mcg to 24 mg 225 mcg to 32 mg per day~B. Buprenorphine (Extended release) 300 mg q 28 days (Sublocade) 100 mg q 28 days (Sublocade) 8 mg q 7 days (Brixadi) 16 mg q 7 days (Brixadi) 24 mg q 7 days (Brixadi) 32 mg q 7 days (Brixadi) 64 mg q 7 28 days (Brixadi) 96 mg q 7 28 days (Brixadi) 128 mg q 7 28 days (Brixadi)"
RECRUITING
Marshall University Division of Addiction Sciences P.R.O.A.C.T, Huntington
RECRUITING
Hennepin Healthcare Addiction Medicine, Minneapolis
RECRUITING
Rapid Start Clinic, Kaiser Permanente Colorado, Denver
RECRUITING
Outpatient Buprenorphine Induction Clinic, University of California, San Francisco, San Francisco
RECRUITING
Highland Hospital Bridge Clinic at Alameda Health System, Oakland
RECRUITING
Officed Based Addiction Treatment Program, Boston Medical Center, Boston
Collaborators (2)
National Institutes of Health (NIH)
NIH
National Institute on Drug Abuse (NIDA)
NIH
The Emmes Company, LLC
INDUSTRY
University of California, San Francisco
OTHER
Boston Medical Center (BMC)
UNKNOWN
Hennepin Healthcare Research Institute
OTHER
Alameda Health System
OTHER
Marshall Health
UNKNOWN
Kaiser Permanente
OTHER
Yale University
OTHER